NATICK, Mass., Sept. 25 -- Boston Scientific
Corporation (NYSE: BSX - News) today announced that its Maple Grove, MN manufacturing
facility has been named one of the 10 best plants in North America by Industry
Week magazine, a national publication for manufacturing executives. The Maple
Grove facility manufactures cardiovascular products, including the Company's
TAXUS(TM) drug-eluting coronary stent system.
"This is national recognition for our ongoing efforts to create a world- class manufacturing environment at Boston Scientific," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "The award is further evidence that we are making solid progress toward our goal of increasing productivity and enhancing innovation, and that our manufacturing capability is becoming a competitive advantage for us in the marketplace. Industry Week is the gold standard, and virtually every member of the Maple Grove manufacturing team should take a great measure of pride and satisfaction in this achievement."
According to the magazine, the annual Best Plants award was created in 1990 to "recognize plants that are on the leading edge of efforts to increase competitiveness, enhance customer satisfaction, and create stimulating and rewarding work environments."
Editors at the magazine said that this year's Best Plants winners "have made incredible changes in the way they run their operations, aligning their production processes with customer needs and harnessing people's desire to make things better."
Plants are judged by a panel of Industry Week editors, who solicit independent evaluations from manufacturing experts. Each year, the magazine recognizes 10 manufacturing plants as the "best plants" in North America. The 10 facilities are not ranked individually but honored as a group.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, operational improvements, and other factors described in the Company's filings with the Securities and Exchange Commission.
| Contacts |
|
Milan Kofol (508-650-8569)
Investor Relations
Boston Scientific Corporation |
Paul Donovan (508-650-8541)
Media Relations
Boston Scientific Corporation
|
|